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a b s t r a c t
Regenerative medicine (RM) is championed as a potential source of curative treatments for a variety of
illnesses, and as a generator of economic wealth and prosperity. Alongside this optimism, however, is a
sense of concern that the translation of basic science into useful RM therapies will be laboriously slow
due to a range of challenges relating to live tissue handling and manufacturing, regulation, reimburse-
ment and commissioning, and clinical adoption. This paper explores the attempts of stakeholders to
overcome these innovation challenges and thus facilitate the emergence of useful RM therapies. The
paper uses the notion of innovation niches as an analytical frame. Innovation niches are collectively
constructed socio-technical spaces in which a novel technology can be tested and further developed,
with the intention of enabling wider adoption. Drawing on primary and secondary data, we explore the
motivation for, and the attempted construction of, niches in three domains which are central to the
adoption of innovative technologies: the regulatory, the health economic, and the clinical. We illustrate
that these niches are collectively constructed via both formal and informal initiatives, and we argue that
they reﬂect wider socio-political trends in the social management of biomedical novelty.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
An oft-quoted description of RM deﬁnes it as that which “re-
places or regenerates human cells, tissues and organs, to restore or
establish normal function” (Mason and Dunnill, 2008, 4). Many RM
therapies will involve the use of live cells and tissues to repair
damaged or diseased tissue, and are thus considered radically
distinct from drugs and therapeutic medical devices. Examples
include: generating retinal epithelial tissue from human embryonic
stem cells (hESC) to treat forms of visual impairment (Ramsden
et al., 2013); using bone marrow-derived cells for the treatment
of autoimmune conditions (Ringden and Keating, 2011), and engi-
neering tracheas comprising a donor-derived scaffold ‘seeded’ with
a patient's own cells (Elliott et al., 2012). ‘Regenerative medicine’ is
also applied to therapeutic developments with a history that pre-
dates the term, including gene therapy and bone-marrow trans-
plantation. Despite its apparent distinctiveness, the boundaries of
‘RM’ are not necessarily well-deﬁned and they have been some-
what mutable (Webster, 2013).
As with many biomedical developments, high expectation sur-
rounds RM. The ﬁeld has been animated by promissory future-
orientated statements about its considerable clinical and eco-
nomic value. RM has the potential, it is stated, to deliver curative
treatments for a range of diseases, including diabetes, neurological
conditions, and heart disease, (Department for Business Innovation
and Skills, 2011), and will thus “revolutionise patient care in the
21st century” (TSB UK Research Councils., 2012, 2). For proponents,
this clinical value also holds considerable economic value. RM has
been named by the UK government, for example, as one of ‘Eight
Great Technologies’ that will drive innovation and propel the UK's
growth, and in which the UK can become a global leader (Willetts,
2013).
Alongside this high-expectation is a prevalent discourse of
concern. This is that scientiﬁc advancements will fail to translate
into useful RM therapies, or that the rate of translation will be
laboriously slow, due to its novelty and apparent incommensura-
bility with existing biomedical and health delivery infrastructures.
Healthcare systems and infrastructure, as well as regulatory sys-
tems, have emerged to accommodate conventional therapies based
on drugs and devices, and may then be poorly suited to the
governance and delivery of RM (Tait, 2007). Various initiatives have
set about identifying perceived and linked translational challenges,
* Corresponding author.
E-mail addresses: john.gardner@york.ac.uk (J. Gardner), andrew.webster@york.
ac.uk (A. Webster).
Contents lists available at ScienceDirect
Social Science & Medicine
journal homepage: www.elsevier .com/locate/socscimed
http://dx.doi.org/10.1016/j.socscimed.2016.03.025
0277-9536/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Social Science & Medicine 156 (2016) 90e97
including: safety concerns over the instability of live cells and tis-
sues and their potential to become tumorous; logistical and
manufacturing difﬁculties, particularly a stable scale-up of cell and
tissue production; the regulatory burden; the potentially high up-
front costs of RM products and procedures; and the difﬁculty of
integrating RM therapies into existing workﬂows in clinical settings
(Regenerative Medicine Expert Group, 2015) [hereafter RMEG].
Collectively, such challenges are said to generate levels of risk and
uncertainty that deter investors, particularly venture capital and
large industry (Omidvar et al., 2014). Developments within the RM
ﬁeld, then, are particularly susceptible to the so-called ‘valley of
death’ (Department for Business Innovation and Skills, 2011); the
perceived gap between initial invention and ‘successful’ technology
that ‘translational’ activity is supposed to bridge.
The translational challenge has ﬁgured prominently in debate
(RegenerativeMedicine Expert Group, 2015, House of Lords Science
and Technology Committee, 2013, UK Research Councils., 2012),
and regional and national agencies, such as the California Institute
for Regenerative Medicine (CIRM) in the US and the Cell Therapy
Catapult in the UK (Thompson and Foster, 2013), have been
established to support research, build new infrastructure and
expertise, and to foster commercialisation. Similarly, the UK's
Regenerative Medicine Platform has been established to address
key safety, manufacturing and delivery concerns within the ﬁeld.
The ﬁeld of RM, then, is characterised by a concurrent assem-
bling of new directions in biomedical research, and new socio-
technical networks tasked with delineating, managing and
routinizing these emerging forms of life. These assemblages are
being driven by promissory future-oriented visions (Morrison,
2012), and involve the coordinating of heterogeneous agents (ie,
clinicians, scientists, patients, commercial and not-for-proﬁt en-
terprises) with potentially convergent worldviews and interests.
The ﬁeld, in other words, constitutes a form of collective organising
and social change, propelled by the promise of a future of greater
“health andwealth” (NHS, 2011). It is for this reason that the ﬁeld of
RM provides a rich area for inquiry for the social scientist. It is a
ﬁeld in which jostling entities e whether they be small bioobjects
(Vermeulen et al., 2012), or large institutions e are being enacted
into existence, delineated, and assigned roles which are taken-up,
challenged and renegotiated. It is, in other words, a ﬁeld that is
rich with ‘matters of concern’ (Latour, 2005) which, once
addressed, may become ‘going concerns’ (Rip and Joly, 2012) and so
normalised in clinical practice (May, 2013). Thus, RM provides an
opportunity to examine a key problematic in the social sciences:
how is it that socio-technical change occurs, and how it is that
perceived socio-technical novelty is routinized and normalised. In
this paper, we explore some of the innovation challenges posed by
the ﬁeld of regenerative medicine, and we examine attempts to
manage and harness its biomedical novelty, speciﬁcally within
three domains: the regulatory sphere, the health economic sphere,
and the clinical development sphere.
2. Novelty and its management
Regenerative medicine is among several ﬁelds within the bio-
sciences that have been characterised as novel and transformative,
both in terms of how biological forms of life are manipulated,
engineered and understood (Metzler and Webster, 2011), and the
new challenges they pose for regulatory agencies and wider society
(van Est and Stemerding, 2012). For example synthetic biology
(Calvert, 2013), bio-nanotechnology (Swierstra and Rip, 2007;
Boenink et al., 2010), and the neurosciences (Rose and Abi-
Rached, 2013), are constituted by the emergence of what has
been described as transformative biomedical platforms (Keating
and Cambrosio, 2003), implicated in generating novel entities
that may challenge the very notion of ‘human’ (Bateman et al.,
2015).
This paper adopts the position that novelty and its trans-
formative character are, however, neither self-evident nor intrinsic
to speciﬁc technological developments. What counts as being
“novel” is dependent on a range of socio-technical processes
associated with how perceived novelty is mobilised, embraced,
valued or discounted, and managed. This is true within the lab, the
regulatory universe, the intellectual property domain, and in any
commercial product for markets (Dussauge et al., 2015; Packer and
Webster, 1996). Novelty in this sense is both a claimed social and
technical attribute (Barry, 2001), and in that sense its meaning and
boundaries are never self-evident but are, rather, subject to nego-
tiation by actors. Developments within the biosciences may be
positioned by actors as being simply a valuable extension of
existing practices (and so iterative and non-radical): this is often
associatedwith the incremental innovation associatedwith surgery
(Riskin et al., 2006). In other settings, techniques that are posi-
tioned as assisting conventional practices can also be seen as
radical. This is true, for example, in the ﬁeld of IVF where super-
numerary embryos provide the basis for a reproductive socio-
technology that both extends and opens up opportunities for two
divergent activities: the reproduction of children and, via the pro-
duction of embryonic stem cells, regenerative medicine (Webster,
2007).
Two notable developments in regenerative medicine associated
with claims to novelty were the identiﬁcation and isolation of hu-
man embryonic stem cells (hESC) at the University of Wisconsin-
Madison in 1998, and the creation at the University of Kyoto in
2007 of ‘induced pluripotent stem cells’ (iPS), which are reprog-
rammed from adult human cells and have the biological potential
of hESC. More generally it is the use andmanipulation of live tissues
and cells that are considered to be the basis for the ‘novel’ and
‘transformative’ nature of RM, and extracting, purifying handling,
and storing live tissue is a difﬁcult task, as is manipulating it to
become a differentiated cell and then scaling up that cell without
loss of functionality. This has raised questions about how quality
control, potency and release assays are to be developed and vali-
dated (Ali et al., 2014), the ways inwhich clinical trials are designed
(Mittra et al., 2015; Webster et al., 2011) and how cell therapies are
to be classiﬁed in regulatory terms (as a medicine or a device; see
(Faulkner, 2012b). Coping with material variability and instability
has become a core ‘matter of concern’ in the ﬁeld.
Here, we use the notion of innovation niches (Schot and Geels
(2007) as a conceptual tool to explore novelty and transformation
as it relates to RM. Schot and Geels note that some innovations are
perceived to be so novel that they are regarded by their developers
as incommensurable with the existing socio-technical infrastruc-
ture (or what they call sociotechnical regimes). The success of such
innovations requires the construction of a protected socio-technical
space e what can be called a “technological niche” e that will
provide a ‘seed-bed’ in which the innovation can be nurtured,
tested and further developed. Depending on the perceived desir-
ability of the innovation and the success in enrolling others into the
development, the niche may eventually be expanded to the point
where it becomes a new socio-technical regime, perhaps sup-
planting earlier socio-technical regimes. It is in this way that an
innovation can become widespread, routinized, and thus trans-
formative. Niches are actively constructed by various actors and
thus reﬂect diverse interests and the social and political contexts
within which they are constructed and negotiated. Hence, we use
the notion of ‘innovation niche’ as a conceptual tool to refer to
socio-technical spaces that could, ‘on the ground’, be highly vari-
able in form. It is important to note that while innovation niches are
designed to enable developments that are seen as novel and require
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special handling e and in contexts where the notion of ‘the novel’
has itself been strategically mobilised by actors (see Pickersgill's
[2013] discussion on neuroscience) e not all actors will neces-
sarily agree on how novel such developments are.
National healthcare systems (and international regulation)
engender and reproduce a dominant socio-technical regime which
shapes the development, evaluation, adoption and implementation
of most new therapeutics, principally relating to new drugs and
medical devices. As we will see, commentators and investigators
working within the ﬁeld believe that RM is poorly served e indeed
inhibited e by this socio-technical regime. Initiatives have thus
been launched to actively support the emergence of RM. Drawing
on interview and secondary data, we will explore some of these
initiatives - which can be said to constitute the formation of inno-
vation niches - in three areas: the regulatory, health economic, and
clinical development domains.
These three areas play a central role in the translation process.
Each carries both macro and micro dimensions e reﬂected at the
macro level in formal oversight, evaluation and implementation
requirements as well as how, at a local level these are expressed
within more informal, everyday contexts. In effect they act to make
an innovation workable within speciﬁc contexts and so help to
normalise it (May, 2013). Ethical considerations are also important
in the biomedical context (Salter and Salter, 2013) and are
encompassed here by the ‘regulatory’ domain, though our data and
discussion do not deal with this explicitly in this paper.
3. Methods
The paper draws upon data from the ESRC-funded REGena-
bleMED collaborative research project which explores the social
dynamics of innovation within the RM ﬁeld, with a particular focus
on institutional readiness: how it is that elements of the healthcare
system might enable the workability of RM. We draw on 40 in-
terviews with individuals working within the ﬁeld from across the
UK in different institutional settings, including research labs,
teaching hospitals, companies, patient and professional bodies and
government agencies. Our respondents included clinicians devel-
oping RM products and procedures that are in, or are about to
begin, clinical trials. Speciﬁcally, we sought to include therapeutic
developments that had been identiﬁed by stakeholders as ‘pio-
neering’ or ‘path-breaking’ within the ﬁeld of RM. Our projet
advisory group, which includes patient advocacy representatives,
commercial representatives, and representatives from the public
sector, helped to identify these developments and appropriate
participants. Other participants included scientists working within
academic networks tasked with identifying and overcoming tech-
nical, manufacturing and safety translational challenges; patient
association representatives and members of trade and professional
organisations with involvement in RM; representatives from reg-
ulatory agencies and other national health governance organisa-
tions; and representatives from companies with an interest in RM.
Interviews have been transcribed and subjected to thematic anal-
ysis using NVivo 10 software. Interview data are supplemented by
RM secondary data: publicly-available committee reports and
meeting minutes, company annual reports, and media coverage. In
addition, one of the authors is a member of the Regenerative
Medicine Expert Group and so was party to discussion therein,
though material used here is in the public domain. Thematic
analysis of the dataset was by guided by the ‘innovation niches’
concept, which was used as sensitising tool while analysing the
data. We thus sought to note: how RM is framed by participants;
their perceptions of its innovative form in relation to existing
therapies, their perceptions of the arrangements which either
hinder or enable innovation, and their involvement in attempts to
facilitate innovation. We also noted and analysed their general
impressions and perceptions of RM and how it relates to other ﬁeld
of biomedicine. Ethics approval for this data collection was ob-
tained from the appropriate institutional ethics review board, and
informed consent was obtained from all participants.
4. Findings: the construction of socio-technical niches
There is considerable variation amongst the potential products
and procedures that are deﬁned as being ‘regenerative medicine’,
and participants we spoke to indicated that the speciﬁc trans-
lational challenges encountered in each therapeutic area would
vary. Participants, however, also made reference to some general
translational challenges that affect the ﬁeld as a whole. Generally
participants felt that while basic science was well-supported in the
UK, the current environment was not conducive to RM translation:
I think it's been enabling for basic scientists but not for clinicians
… It is [enabling] if you're a molecular biologist but if you're a
person who is truly translational, no. (CEO)
There's a reasonably good infrastructure and funding to take
things through basic science at universities but there's a trans-
lational hiatus because the costs are high, then a disinterest once
you get pretty close. (Surgeon1)
More importantly, respondents regarded regenerative medicine
as being sufﬁciently distinct, in terms of biological structure and
complexity, that it warranted new translational ‘pathways’. Here a
small RM company CEO believes that the novelty of RM as a tech-
nology meant ﬁrms are reluctant to invest and clinical commis-
sioning managers are reluctant to reimburse (and, implicitly,
regulators to approve):
Not a single one was willing to invest at that point because no
one had done it before. There wasn't a pathway… the technology
hadn't been demonstrated anywhere… (CEO)
These comments reﬂect the general sentiments expressed in
many of the ofﬁcial reports: that the current healthcare system is
poorly suited to accommodating RM (House of Lords Science and
Technology Committee, 2013, UK Research Councils, 2012,
Department for Business Innovation and Skills, 2011). It is this
framing of RM (as complex and novel) and the healthcare system
(as not ‘enabling’ of RM) that has been mobilised to justify and
prompt initiatives that provide a more enabling environment. In
what follows, we explore this delineation of novelty in more detail
as it relates to the creation of three niches, and we provide a
description of the steps that have been taken in each of these areas
to support RM. In each area we focus on the construction of the
niche domain, its relation to existing structures, its formal and
more local dimensions and the negotiations surrounding it.
4.1. The regulatory niche
A major translational challenge, according to commentators, is
the existing regulatory regime which has largely emerged to
accommodate and govern drugs and devices. In this section we
explore the attempts to construct a regulatory niche for RM prod-
ucts and procedures. Wewill see that the construction of this niche
is characterised by formal initiatives, such as the establishment of
the Advanced Therapy Medicinal Products (ATMP) framework, and
more-informal processes ‘on the ground’ that include a pragmatic
negotiation between clinicians and regulators. These initiatives
entail the formation of unique standards, codes and procedures
intended to allay safety and efﬁcacy concerns and to provide a
coherent and ‘enabling’ regulatory environment for RM
investigators.
In 2007 EU institutions ratiﬁed the ATMP regulatory framework
(European Parliamant and Council of the European Union, 2007). It
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represents an important regulatory response to the perceived
novelty of developments within RM (Faulkner, 2012a), and the
most notable attempt tomitigate concerns about safety and quality.
The framework itself reﬂects how key policy-making stakeholders
have apprehended the ﬁeld of RM, and it reveals how they antici-
pate its future development. The collective effort that led to the
framework, and the implications of the framework have been dis-
cussed in detail elsewhere (see Faulkner, 2012a), but it is worth
highlighting some of its key features. It introduced, for example, a
central marketing authorisation procedure, in which prospective
therapies would be assessed (having undergone clinical studies), by
the specially-created multidisciplinary Committee for Advanced
Therapies (CAT). It also introduced post-market surveillance rules
so that the longer-term safety of products can be assessed, and it
stipulated a 30-year traceability requirement as a way of mitigating
safety concerns (Faulkner, 2012a). Additionally, the regulation has
meant that the manufacturing of RM products has to take place in
carefully controlled clean spaces: facilities licensed as being of
clinical Good Manufacturing Practice (GMP) grade. In an attempt to
lessen the ﬁnancial burden of obtaining central marketing
authorisation, the regulation also introduced a substantial licence
fee waiver for small companies, reﬂecting a key concern that was
voiced during deliberations over the framework, that any such
regulation should not unduly hinder innovation. Indeed, the EU-
wide Regulation is framed as replacing divergent national ap-
proaches to governing RM, “which hampered growth of this
emerging industry” and “hindered patients access to products”. The
Regulation, in contrast, was designed to “facilitate access to the EU
market and to foster the competitiveness of European Companies
in the ﬁeld” (Director-General for Health and Food Safety, 2015).
The framework represents the establishment of speciﬁcally-
designed regulatory niche, which has the effect of conﬁrming RM
as ‘distinct’ from other, more conventional areas of medicine, yet at
the same time seeking to manage and normalise its biomedical
novelty.
At the same time, this component of the niche sits within and
builds upon an existing regulatory regime to which RM de-
velopers must also respond. Depending on the source and nature
of cells or tissues used, the nature of other components, and the
stage of translational development, RM products and procedures
within the UK may also be subject to governance by the Human
Fertilisation & Embryology Authority (HFEA), the Human Tissues
Authority (HTA), and the Medicines and Healthcare products
Regulatory Agency (MHRA, which also implements the ATMP
framework within the UK). Navigating a route through these au-
thorities has been identiﬁed as a considerable challenge by ad-
vocates of RM. The House of Lords Science and Technology
Committee's inﬂuential Report (2013) on RM in the UK notes that
RM stakeholders felt that the regulatory environment was “laby-
rinthine and off-putting for overseas investigators, whilst
demoralising for home investigators” (2013, 38), and it suggested,
therefore, that a regulatory advice service be established. Conse-
quently, a “one stop shop” regulatory advice service spanning the
HFEA, HTA and MHRA has been established, speciﬁcally for
regenerative medicine. It is claimed that bringing together the
relevant regulatory bodies into a single access point will “smooth
the translational pathway for all those UK workers engaged in
regenerative medicine” (MHRA, 2014). Here we see an attempt to
align new and existing regulatory components.
In addition to these formal top-down regulatory initiatives,
more localised processes across the science base are contributing
to the construction of a regulatory niche for RM. Regulatory pro-
visions such as the ATMP framework aim to ensure that clinical
trial participants are not subjected to unnecessary levels of risk,
and that only those therapies that meet minimum safety and
efﬁcacy requirements will be offered to patients on a routine
basis. Yet, according to respondents, precisely how safety and
efﬁcacy should be assessed is not clear, and the guidelines used for
drugs and devices may not e depending on the nature of the
therapy, be appropriate. Cells and tissues within RM are perceived
to be more “complex” than drugs and devices, and this creates
particular challenges:
The real obstacle is that as cell therapy is a complex product it
can never ever be analysed to the degree that even a biophar-
maceutical can… (Surgeon1)
And clinical trials conventions are equally problematic:
One of the biggest things is the standard deviations. So, if you're
going to produce a drug, you would expect that you're going to
be giving exactly the same formulation, exactly the same dose,
exactly the same quality control every single time you give it.
But cells have such variability that you simply can't do that.
You're, therefore, looking at maybe 20 percent variation in
certain quality control parameters, far, far greater than you
would in any other medicinal products. (Cell scientist1)
This is, according to respondents, particularly problematic in
regards to therapies that use cells or tissues derived from plurip-
otent cells. Any residing ‘pluripotent potential’ may manifest in the
form of tumours:
If you start with an already differentiated cell, ‘purity’ is not an
issue (since the characterisation/stability etc. has been done/
secured); the main issue is efﬁcacy. If you start with a pluripo-
tent cell, you need 100% purity in the assay to avoid tumorige-
nicity’. (Cell scientist1)
Respondents argued it was therefore necessary to develop new
standards that could be used to assess quality and safety, based on
standardised assays and the identiﬁcation of appropriate bio-
markers, phenotypical traits that are easily detectable, and indic-
ative of the cell or tissue's safety and efﬁcacy:
‘MHRA's traditions have been based on purity of a drug/com-
pound e 99% pure … But with a cell (an MSC) can't make the
same statement (cant ‘purify’ in the same way) so we rely
heavily on being able to show that you have key biomarkers that
show safety and efﬁcacy. (Cell scientist1)
It is these concerns that prompted the formation of a ‘safety and
efﬁcacy’ hub as part of the UKRMP, the ofﬁcial aim of which is to
“provide clearer understandings of the potential hazards with [RM
technologies] and to develop new methodologies to assess their
risk”. As with all the UKRMP hubs, the safety and efﬁcacy hub
employs a multi-centred, multidisciplinary methodology, bringing
together expertise from several key disciplines. It represents an
attempt to create a novel biomedical platform: a particular set of
standards, tools and protocols that can facilitate translation.
Finally, in the process of designing clinical trials, the clinicians
we spoke to have also been attempting to formulate standards for
assessing safety and efﬁcacy for speciﬁc RM therapies. This has
involved negotiations with MHRA ofﬁcials who, they say, initially
had very little understanding of how the quality of RM products
and the safety of RM therapies should be assessed. This ‘matter of
concern’ was yet to be properly articulated on both sides: as one
biomedical scientist said,
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How do I get to understand what it is that you [the MHRA] need
if I don't know what questions I need to ask of you? (CEO)
And similar comments were:
I felt great sympathy for them because they are, like everybody
else, understaffed and they don't have anybody there who has
any previous experience because these are completely new, in a
sense, to this [product]. (Surgeon2)
You go back when you start some years ago, the knowledge
about regulation was very limited from both ways … even the
regulators themselves they didn't know exactly what to do.
(Surgeon3)
So, we've had to have more meetings with MHRA than you
might normally think and they have had to learn on the job as
well. (Surgeon2)
Through iterative negotiation, these clinicians are formulating
quality and safety standards that, while not ideal, are satisfactory
for the MHRA, especially when there is considerable clinical need
for the procedure:
Yes, deﬁnitely but it's almost as though, when we have the
meetings, [the MHRA] are saying to us, “Well, what's the best
you can …” And there's something about these patient groups
being particularly in need, being orphan1 and particularly ill in
that sense. So that, I would guess, feeds into theMHRA's feelings
on this. (Surgeon2)
Thus, for some therapeutic developments, particularly in those
clinician-led projects that are more advanced along the trans-
lational pipeline, quality control and safety protocols are being
developed via pragmatic negotiation between clinicians and reg-
ulators. The approach here is to generate some of the standards by
which subsequent RM products and procedures that are deemed
similar will be judged.
In effect, a regulatory niche for nascent RM therapies is being
collectively constructed in a variety of formal and informal ways.
Some aspects of the niche, such as the MHRA regulatory advice
service, build upon existing regulatory provisions and articulate
with more formal initiatives, such as the ATMP framework, and
other aspects are established through pragmatic negotiation at the
local level.
4.2. The health economics niche
Another translational challenge for any innovative biomedical
therapy relates to reimbursement and commissioning. In many
countries the decision to commission a therapy depends heavily on
the results of a formal technology appraisal which determines
whether it is clinically and cost effective, and thus whether it
should replace or complement existing services. In the UK this is
undertaken by the National Institute for Health and Care Excellence
(NICE) and it involves a Quality Adjusted Life Year (QALY)-based
cost-utility analysis: the cost of the therapy is compared to that of
the existing standard of care, relative to the added clinical beneﬁt
(measured in terms of QALYs). Those therapies that are accompa-
nied by robust and comprehensive data on cost and clinical beneﬁt
are more likely to receive a favourable technology appraisal,
important for their marketability. Our respondents felt that such a
system is not well suited to RM products and procedures, and may
then place them at a disadvantage.
A common point made by respondents was that RM products
and procedures would likely, at least initially, have a high upfront
cost (due to the investment required to produce and support them).
While in the longer term they may bring about cost savings, this
high-upfront cost would disadvantage them under the current
appraisal system used by NICE, which reﬂected the reimbursement
structure of the healthcare system more generally. As a director of
an RM centre stated:
The bad thing about the UK is NICE… Because cell therapies are
almost certain to cost almost as much as biologics and biologics
are very expensive. The reimbursement system at the moment
…, isn't very good.… Paying a lot of money this year to save an
awful lot of money down the line - the government as you know
can't do that… So that's an obstacle. (Cell scientist2)
Another issue relates to the requirement for robust and
comprehensive data necessary for a technology appraisal. Partici-
pants noted that the data required was not the same as that which
would be submitted as part of a central marketing authorisation.
This meant that two ‘streams’ of data need to be collected during
clinical studies, which was a major hurdle for the small enterprises
that typify the RM commercial landscape. This issue is complicated
by some ambiguity over the type of data that are required, and the
alleged lack of guidance from NICE. These issues are illustrated in
an extract from an interview with a CEO of a small company
developing an RM product:
But some of the comments that I heard from NICE recently at [a
talk] sent shivers down my spine … [they] pretty much dis-
missed data that was presented to them … It was data the
MHRA wanted or the EMA wanted or the FDA wanted so it got
the product approval to market but NICE essentially said, “We
don't care about any of that. It's not in the right format, it's not
addressing things we need to know about”; yet they wouldn't
necessarily say what those things are and the [NICE rep] bluntly
said, “We'll answer a direct question but we won't give you
guidance” … we've got enough on our hands both ﬁnancially
and logistically and have more kinds of ways to navigate the
regulatory pathway. Then to have a parallel pathway that may
require a completely different set of clinical data; we just can't
afford to do two sets of clinical work. I don't know how we get
that feedback early enough so we can design our clinical data to
feed both streams. (CEO)
These points have also been raised in several reports exploring
translational challenges in RM (House of Lords Science and
Technology Committee (2013)), which have noted that in-
vestigators may be unable to meet the requirements for robust and
comprehensive economic and clinical effectiveness data. The dif-
ﬁculty here is that such data can only be generated if the therapy is
being regularly used; yet without such data, it is unlikely to be
adopted into routine therapy. In response to these challenges, the
House of Lords Science and Technology Committee report
concluded that the NICE methodology is inappropriate for
appraising RM therapies (2013).
As we saw in regard to regulation, creating a niche to address
these challenges has meant engaging with and building upon
existing provisions. One such provision is the ‘risk-sharing’ model
where the initial ﬁnancial risk of introducing a new therapy into the
healthcare system is shared between industry, the government,1 Products with an ‘orphan’ designation are targeted at rare, life threatening
illnesses for which there is no alternative treatment.
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and the NHS. The RMEG argued that this should be used for RM. It
was also thought that the current ‘commissioning through evalu-
ation’ scheme, in which the NHS sets aside funds for trialling a
therapy in a clinical setting, might be appropriate. The RMEG has
also recommended that NICE establishes a scientiﬁc advice service
speciﬁcally for the SMEs involved in RM development.
However, none of these spaces deals directly with the key issue
of QALYs and the evidence that is needed to make robust cost-
effectiveness calculations. The RMEG has therefore seen the need
to take a further and more radical step in creating an appropriately
framed health economics niche for RM by commissioning a ‘mock
appraisal’ of a cell therapy that could assess whether, and if so in
what way, existing NICE methodology needs to be changed to
accommodate the particular characteristics of RM. It also stated
that the agency should ‘… seriously consider developing amethods
and process manual for regenerative medicine or incorporate into
existing documentation’ (RMEG Minutes, Sept 2014). A mock
appraisal was subsequently approved, but this raised an additional
dilemma: what speciﬁc therapy could be used as an exemplar for
RM? What characteristics, in other words, would constitute an RM
exemplar, and could this be used to adequately test the existing
socio-technical regime? There was considerable discussion and
negotiation over this in the RMEG. The eventual choice was to use
T-Cell therapy used in oncology, but the Minutes of the RMEG
discussion reﬂect the lack of complete consensus:
‘a number of voices indicating that an oncology cell therapy was
not a good example. A better and more relevant example would
be a true regenerative medicine therapeutic for the treatment of
a chronic degenerative disease, particularly one that affected the
older population’ (Ibid).
At the time of writing the appraisal remains incomplete, but this
debate over the exemplars highlights how deﬁning a product is key
to deﬁning an innovation niche. When the results of the review are
published (in spring 2016) we are likely to see further negotiation
over the results, and how they impinge on the formal processes of
appraisal adopted by NICE.
4.3. The clinical development niche
A third key challenge for an innovative therapy is how it can be
adopted and implemented in existing clinical practice (Ulucanlar et
al., 2013). The technical and logistical infrastructure, payment
systems, and staff training in clinical centres have been closely
associated with drug and device-based therapies. Such centres may
therefore lack the capacity and competency to implement new RM
therapies that, due to the live and complex nature of their con-
stituent cells and tissue, will require bespoke logistical systems for
the sourcing and movement of cells, and specially-trained staff. An
‘enabling’ clinical niche has been built in several ways.
First, respondents spoke about ways in which they could
mobilise aspects of the current clinical infrastructure, both in terms
of particular technical and related regulatory assets. A key resource
has been the NHS Blood and Transplant (NHSBT) service. Within
the NHS, NHSBT centres are largely responsible for collecting and
distributing products for transfusion or transplantation (including
bone-marrow transplantation), and thus have extensive experience
in handling live tissue, logistics, and managing the associated reg-
ulatory hurdles. For several of our respondents involved in the
development of a tissue-engineered product, the NHSBT was key to
their RM project. This particular product had been implanted in
several ‘compassionate use’ cases, and is currently undergoing
phase I/II clinical trials.
We can't afford to buy and build facilities so we're using the
facilities at the NHSBT who have got state of the art facilities to
do [product constituent] processing … So we're using essen-
tially those guys as contract facilitators. (CEO)
They're an existing resource and they have been involved in
tissue procurement from human sources for a long, long time…
they have particular expertise that we've been able to leverage
on. So they're sourcing the [product] for us… [They have been]
delivering routine cell therapies for haematological diseases. So
we're able to use that kind of expertise of how to deliver cells or
cellularised products, in this case, to GMP standards and that's
been utterly crucial in making this a goer, really. (Surgeon2)
As this respondent notes, a key aspect of NHSBT is their capacity
to produce products within facilities that meet rigid GMP standards
- a requirement for all ATMP products intended for clinical use.
Another way in which existing structures have been important
has been the role of research-intensive NHS Trusts which have
infrastructural elements that are orientated towards innovation:
respondents report on how the Trusts had facilitated their RM
projects. As one observed:
We've got this very nice and well understood relationship with
the Trust which is where [the project has] got a clinical
component… it's got a research component - that's what we're
good at [and] whenwe put them together - So it works very well
and it's an interesting model actually to look at… I don't think
anybody is as fortunate as us in having such a good clinical
environment behind the medical school.
Due to its geographical position within the UK, this particular
Trust provides a range of specialist clinical services, including bone-
marrow transplantation services. It operates a GMP facility and has
expertise in handling and manufacturing blood and tissue
products.
Because [location] is remote from other places, it does all the
specialities… in fact the cell manufacturing facility is run by the
Trust… it's that understanding of the regulatory requirements,
it's also that we built a manufacturing centre.… so we've got a
good number of clinical trials in stem cells.
Indeed, respondents at other research-intensive trusts involved
in RM clinical trials mentioned the importance of having easy ac-
cess to established cell-manufacturing facilities, and in particular,
close alliances between cell-scientists within those facilities and
clinicians:
Then at the [hospital] is [cell scientists]. He's a world leader in
cell therapy manufacture. He's involved in lots of different
projects with different companies, has a great facility for GMP
manufacture of cell products … he's well placed from a regu-
latory perspective, as well, to guide us. (CEO)
I've worked with [cell scientist] who's very senior and well
respected researcher in stem cells and together we've looked at
combining developments in both clinic and laboratory tech-
nique at the same time. And we… run the clinical development
of delivery, the surgery, the patients, everything at the same
time as developing the cells we were going to transplant so that
it would be a shorter timeframe, that's the gist of the project.
(Surgeon1)
Respondents mentioned other features of the existing system
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that have helped them deliver RM products or procedures to pa-
tients. These included supportive ethics committees, competent
clinical trial units, and clinicians with the time and expertise to
manage the onerous regulatory requirements. In effect, these Trusts
constitute a clinical niche not found across the NHS for developing
RM products and procedures. They are enabling the collection of
safety and efﬁcacy data, but importantly, they also provide an op-
portunity for investigators to develop and test some of the sup-
porting socio-technical infrastructure that would be required if the
therapy were to be offered routinely, infrastructure that relates to,
for example, logistics and therapy administration, clinical outcome
data collection, and personnel skill.
Indeed, the importance of these clinical contexts to the eventual
embedding of RM in the healthcare system has been recognised in
the RMEG's report (2015). The report suggests that such centres,
which have ‘experience in the development of regenerative medi-
cines’ should become the basis of Cell Therapy Centres of Excel-
lence. Investment, specialist resources and skills, the report
suggests, should be further consolidated around such centres to
create a coordinated network supporting further RM research and
the routine treatment of patients. The report recommends that
various bodies (the Department of Health, BIS, NHS England, and
the Cell Therapy Catapult) be involved in the process of identifying
such centres and examining how they can best be coordinated and
consolidated. Here we see the way in which a bottom-up innova-
tion process in particular clinical contexts leads to moves towards a
more formalised clinical niche for emergent RM therapies.
5. Discussion: enabling novelty in RM
The formulation of the three niches involves the creation of sites
which, it is hoped, will provide an innovation space for RM. As we
have seen, this entails engaging with, and where possible, mobi-
lising, the existing sociotechnical infrastructure. In addition, the
niche-constructing initiatives have a recursive relationship, inas-
much as stakeholders are aware that a niche in any one of the three
domains will only be effective if it makes wider sense. As was noted
by the RMEG:
‘evenwhere [RM] products were in truth clinically effective, this
may not be known with a high level of certainty at the time an
ATMP ﬁrst comes to market. Exploring the impact of a limited
evidence base on the NICE appraisal should be a major consid-
eration of this study.’
ATMP regulatory provisions, NICE economic appraisal, and
clinical considerations, as the extract suggests, need be considered
as inter-related. A consequence of this is that a range of actors
spanning various domains are involved in the formatulation of
niches, and boundaries are not clear-cut. Indeed, the boundaries of
each niche can be deﬁned in formal terms e such as a regulatory
change (the ATMP provisions) e or informally, such as in emergent
centres of collaboration within speciﬁc Trusts.
Some features of emerging niches, particularly formal aspects,
may be more obdurate than others and have widespread effects.
The ATMP framework, which stipulates that those RM products and
procedures classiﬁed as ‘ATMP’ must be manufactured according to
GMP standards, is an example of this: as we have seen the niche-
forming activities in the clinical domain has involved mobilising
the GMP facilities of the NHSBT infrastructure.
The niches make an important contribution to socio-technical
change by opening up speciﬁc spaces where negotiation of the
potential role and value of RM is enabled and where resources e
regulatory, economic and clinical organisational e are mobilised.
Together these three niches are helping to manage the novelty and
‘matters of concern’ posed by RM. These concerns derive from the
bio-social problem of deriving, handling, stabilising and deploying
live tissue which has been manipulated and, thereby, is not, in
regulatory terms ‘viable in nature’. Making it viable in healthcare
systems requires considerable work. The niches explored here
provide some of the key spaces that help to coordinate efforts to
establish a broader socio-technical infrastructure for RM and make
the eventual routinisation of the RM ﬁeld more possible. Without
them, it is likely that RM would remain a marginal and clinically
very limited ﬁeld. They are part of what in STS and innovation
studies can be seen as the co-production of technologies and
(clinical) markets (Coombs et al., 2003). However, the construction
of niches can be a difﬁcult and contentious process. For example,
although the ATMP framework was positioned by proponents as a
means to support RM, some investigators within the ﬁeld have
found it onerous: one responded described it as committing a
‘category mistake’, by deﬁning cell therapy as a medicine rather
than a device (which has less onerous regulation). Similarly, NICE's
mock appraisal is based on an exemplar that may be far from
generalisable. In both cases we see that the development of niches
poses epistemic ‘matters of concern’ for some of the actors
involved.
The construction of the niches reﬂect broader socio-political
trends in the management of biomedical novelty; trends that
may be opening-up current delivery and governance systems (the
current regime) to regenerative medicine. These include a move-
ment towards reconceptualising regulatory bodies as facilitators of
innovation, rather than as simply mechanisms to protect the public
from unsafe or ineffective interventions. This movement can be
seen as what some authors have referred to as a ‘proactionary
approach’ (Fuller and Lipinska, 2014) to regulation in which
calculated risk-taking is seen as central to innovation (Mittra, 2016).
This has been noted, for example, in the FDA's response to phar-
macogenetics (Hogarth, 2015), and in more general calls for ‘smart
regulation’ for speedier product approval processes, such as via
progressive licensing/adaptive licensing arrangements. Such ini-
tiatives may be co-opted and mobilised in the development of RM
innovation niches, and they may subsequently constitute a broader
change in the ‘socio-technical regime’ (Geels, 2004). In regard to
pharmaceuticals, commentators have argued that this reconﬁgu-
ration of regulation is indicative of the increasing inﬂuence of
commercial interests, particularly big pharma, in agenda setting for
policy (Davis and Abraham, 2013). What we are seeing currently in
regenerative medicine, however, is that the emerging regulatory
niche is a consequence of a variety of initiatives each involving
various interests. Key aspects of the emerging regulatory niche, for
example, are the consequence of pragmatic negotiation between
clinicians and UK regulators.
Another broader socio-political trend reﬂected in the initiatives
to facilitate regenerative medicine is the instrumentalisation of the
healthcare system as a machine for innovation and of wealth
generation. In the UK, this is reﬂected in the emerging discourse on
‘health and wealth’ that surrounds the NHS (c.f. DOH, 2011). It can
also be seen in initiatives such as the combining of patient DNA
records in the government led ‘100,000 Genomes’ project (Davis
and Bale, 2014), and indeed the Health & Social Care Act 2012
which has designated research and innovation as key re-
sponsibilities for the NHS (2011). The formal recognition of some
clinical sites as Centres of Stem Cell Excellence, for example, can be
seen as a reﬂection of this trend.
6. Conclusion
The paper has argued that the three niches e of general
importance to all emerging technologies - reﬂect speciﬁc socio-
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technical spaces through which the stabilisation and management
of regenerative medicine is made possible. They have emerged in
response to perceived innovation challenges relating to the myriad
of relevant regulatory tools, uncertainties about how to implement
such tools, the potential high costs of emerging therapies, and
logistical and delivery infrastructures within the clinic. These
niches may serve to take RM beyond the restricted domain of
clinician-dependent individual therapies (in which clinician may
deploy cell therapies on a compassionate use basis for individual
patients) and, in principle open up the possibility of a scaled-up RM
ﬁeld that becomes a ‘going concern’. We have shown how within
each niche we found processes relating to its creation, its articu-
lation with existing structures, the role of both formal and more
informal practices, and sites for negotiation among different
parties. We expect that developments elsewhere e such in syn-
thetic biology or neuroscience e could usefully be interrogated in a
similar way by social science seeking to make sense of emerging
medicine. Moreover, such work could help shape policy by showing
how niche formation occurs and how formal policy-driven and
informal processes might be optimally aligned.
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